Int Ophthalmol Clin. 1987 Winter;27(4):273-333. doi: 10.1097/00004397-198702740-00007.
The principles exemplified by the preceding case reports are summarized below. 1. Although the presence of DRS high-risk characteristics is the single most important indication for initiating scatter photocoagulation, intraretinal lesions suggesting ischemia (soft exudates, IRMA, venous beading, arteriolar abnormalities, and moderately severe hemorrhages and/or microaneurysms) are also important. When these lesions are severe, rapid progression is likely, and initiation of scatter photocoagulation should be considered for at least 1 eye, even when new vessels are absent or mild (Cases 3, 5, 9, and 11). Both eyes should be followed carefully, whether treated or not, and special attention to blood pressure and renal status may be important. When these intraretinal lesions are mostly absent or mild, progression of PDR may be very slow (Cases 1, 6, and 7). 2. NVD are the single most important prognostic feature of diabetic retinopathy, and when they are well established (i.e., greater than or equal to DRS Standard Photograph 10A), the indication for initiation of scatter photocoagulation is strong (Cases 7, 8, 10, and 11). 3. NVE in the absence of vitreous or preretinal hemorrhage or the severe intraretinal lesions listed in item 1 are a weaker indication for photocoagulation, and careful observation of such eyes is a reasonable alternative to prompt treatment. 4. The initial vitreous or preretinal hemorrhage in eyes with PDR is rarely so large that photocoagulation cannot be carried out before a subsequent larger hemorrhage occurs, provided patients report symptoms and are examined promptly. In such cases it is prudent to treat the lower quadrants first, if possible, before they become obscured by hemorrhage (Cases 3-7 and 9-11). 5. Even after full scatter photocoagulation, with burns placed no more than one-half burn diameter apart, there is ample room for additional treatment between scars, and this often seems to be effective in encouraging regression of new vessels that remain or recur after the completion of the initial treatment. Such additional scatter treatment may be concentrated in areas of NVE (Cases 2 and 5) or applied throughout the fundus (Cases 4 and 9-11). Extension of scatter photocoagulation into the posterior pole also appears to be effective sometimes (Case 8). 6. Knowledge of the tendency for new vessels to follow a cycle of proliferation and regression is important when considering additional scatter treatment when new vessels fail to regress or recur after initial scatter treatment.(ABSTRACT TRUNCATED AT 400 WORDS)
上述病例报告所体现的原则总结如下。1. 虽然存在糖尿病视网膜病变严重程度评分(DRS)高风险特征是启动散射光凝治疗的最重要单一指征,但提示缺血的视网膜内病变(软性渗出、视网膜内微血管异常、静脉串珠样改变、小动脉异常以及中度严重的出血和/或微动脉瘤)也很重要。当这些病变严重时,病情可能迅速进展,即使没有新生血管或新生血管轻微,也应考虑至少对一只眼启动散射光凝治疗(病例3、5、9和11)。无论是否接受治疗,双眼均应密切随访,特别关注血压和肾脏状况可能很重要。当这些视网膜内病变大多不存在或轻微时,增殖性糖尿病视网膜病变(PDR)的进展可能非常缓慢(病例1、6和7)。2. 视盘新生血管(NVD)是糖尿病视网膜病变最重要的预后特征,当它们明确存在时(即大于或等于DRS标准照片10A),启动散射光凝治疗的指征很强(病例7、8、10和11)。3. 在没有玻璃体或视网膜前出血或第1项中列出的严重视网膜内病变的情况下,视网膜新生血管(NVE)作为光凝治疗的指征较弱,对这类眼睛进行仔细观察是替代立即治疗的合理选择。4. PDR患者最初的玻璃体或视网膜前出血很少会大到在随后发生更大出血之前无法进行光凝治疗,前提是患者报告症状并能及时接受检查。在这种情况下,如果可能的话,谨慎的做法是先治疗下方象限,以免它们被出血遮挡(病例3 - 7和9 - 11)。5. 即使在进行全视网膜散射光凝治疗后,光斑间距不超过半个光斑直径,在瘢痕之间仍有足够的空间进行额外治疗,这似乎常常能有效促使初始治疗完成后残留或复发的新生血管消退。这种额外的散射治疗可集中在NVE区域(病例2和5)或应用于整个眼底(病例4和9 - 11)。将散射光凝扩展到后极部有时似乎也有效(病例8)。6. 在考虑对初始散射治疗后新生血管未消退或复发的情况进行额外散射治疗时,了解新生血管增殖和消退周期的趋势很重要。(摘要截断于400字)